Back to Annual Meeting

Back to Annual Meeting

Abstract #158148

Beth Han, MD, PhD, MPH, James Colliver, PhD, and Joe Gfroerer, BA. Substance Abuse & Mental Health Services Administration, U.S. Department of Health and Human Services, 1 Choke Cherry Road, Rm 7-1010, Rockville, MD 20850, 240-276-1272, Beth.Han@samhsa.hhs.gov

This is the first study examining the complex relationship between illicit drug use and health conditions based on a recent nationally representative sample of 130,000 respondents. Starting in 2005, the National Survey on Drug Use and Health (NSDUH) included items on health conditions respondents experienced in their lifetime and in the past year. These conditions include asthma, bronchitis, cirrhosis of the liver, depression, diabetes, heart disease, hepatitis, high blood pressure, HIV/AIDS, lung cancer, pancreatitis, pneumonia, sexually transmitted disease, sinusitis, sleep apnea, stroke, tinnitus, tuberculosis, and ulcers. First, we present the prevalence of these conditions among the general U.S. population and among users of illicit drugs, alcohol, and tobacco in the United States. Second, we investigate the specific relationship between the use of specific illicit drugs and health conditions, while controlling for factors, such as age, gender, race/ethnicity, education, health insurance, alcohol and tobacco use. In addition, relevant policy implications will be discussed.

Learning Objectives:

• (1) Assess the prevalence of health conditions among the general U.S. population and among users of illicit drugs, alcohol, and tobacco in the United States.
• (2) Analyze the specific relationship between the use of specific illicit drugs and health conditions.
• (3) Recognize relevant policy implications.

Keywords: Substance Abuse, Co-morbid

Related Web page: www.oas.samhsa.gov/nhsda.htm

Presenting author's disclosure statement:

Any relevant financial relationships? No
Any institutionally-contracted trials related to this submission?

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.